Leo Kit Cheung Lee

Leo Kit Cheung Lee

Auto-generated profile, based on publicly available information

Leo Kit Cheung Lee

Department of Biomedical Engineering, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong SAR

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2021 in Nano Letters
Verified
Journal Article
Closed access
RHRuifang Han
Ruifang Han
LHLok Wai Cola Ho
Lok Wai Cola Ho
QBQianqian Bai
Qianqian Bai
CCCecilia Ka Wing Chan
Cecilia Ka Wing Chan
LLLeo Kit Cheung Lee
Leo Kit Cheung Lee
Chung Hang Jonathan ChoiChung Hang Jonathan Choi
Chung Hang Jonathan Choi

19 September 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
QBQianqian Bai
Qianqian Bai
YXYu Xiao
Yu Xiao
HHHuiling Hong
Huiling Hong
XCXiaoyun Cao
Xiaoyun Cao
LZLei Zhang
Lei Zhang
Chung Hang Jonathan ChoiChung Hang Jonathan Choi
Chung Hang Jonathan Choi
Atherosclerosis treatments by gene regulation are garnering attention, yet delivery of gene cargoes to atherosclerotic plaques remains inefficient. Here, we demonstrate that assembly of therapeutic oligonucleotides into a three-dimensional spherical nucleic acid nanostructure improves their systemic delivery to the plaque and the treatment of atherosclerosis. This noncationic nanoparticle contains a shell of microRNA-146a oligonucleotides, which regulate the NF-κB pathway, for achieving transfection-free cellular entry. Upon an intravenous injection into apolipoprotein E knockout mice fed with a high-cholesterol diet, this nanoparticle naturally targets class A scavenger receptor on plaque macrophages and endothelial cells, contributing to elevated delivery to the plaques (∼1.2% of the injected dose). Repeated injections of the nanoparticle modulate genes related to immune response and vascular inflammation, leading to reduced and stabilized plaques but without inducing severe toxicity. Our nanoparticle offers a safe and effective treatment of atherosclerosis and reveals the promise of nucleic acid nanotechnology for cardiovascular disease.


9 October 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
CCCecilia Ka Wing Chan
Cecilia Ka Wing Chan
CSCheuk Chun Szeto
Cheuk Chun Szeto
LLLeo Kit Cheung Lee
Leo Kit Cheung Lee
YXYu Xiao
Yu Xiao
BYBohan Yin
Bohan Yin
Chung Hang Jonathan ChoiChung Hang Jonathan Choi
Chung Hang Jonathan Choi
Nanomedicines for treating chronic kidney disease (CKD) are on the horizon, yet their delivery to renal tubules where tubulointerstitial fibrosis occurs remains inefficient. We report a folic acid-conjugated gold nanoparticle that can transport into renal tubules and treat tubulointerstitial fibrosis in mice with unilateral ureteral obstruction. The 3-nm gold core allows for the dissection of bio–nano interactions in the fibrotic kidney, ensures the overall nanoparticle (~7 nm) to be small enough for glomerular filtration, and naturally inhibits the p38α mitogen-activated protein kinase in the absence of chemical or biological drugs. The folic acids support binding to selected tubule cells with overexpression of folate receptors and promote retention in the fibrotic kidney. Upon intravenous injection, this nanoparticle can selectively accumulate in the fibrotic kidney over the nonfibrotic contralateral kidney at ~3.6% of the injected dose. Delivery to the fibrotic kidney depends on nanoparticle size and disease stage. Notably, a single injection of this self-therapeutic nanoparticle reduces tissue degeneration, inhibits genes related to the extracellular matrix, and treats fibrosis more effectively than standard Captopril therapy. Our data underscore the importance of constructing CKD nanomedicines based on renal pathophysiology.

18 April 2022 in Nano Letters
Verified
Journal Article
Closed access
HLHuize Li
Huize Li
LHLok Wai Cola Ho
Lok Wai Cola Ho
LLLeo Kit Cheung Lee
Leo Kit Cheung Lee
SLShaorui Liu
Shaorui Liu
CCCecilia Ka Wing Chan
Cecilia Ka Wing Chan
Chung Hang Jonathan ChoiChung Hang Jonathan Choi
Chung Hang Jonathan Choi

25 June 2020 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
LLLeo Kit Cheung Lee
Leo Kit Cheung Lee
LLLok I Leong
Lok I Leong
YLYao Liu
Yao Liu
MLMeihua Luo
Meihua Luo
HCHo Yin Edwin Chan
Ho Yin Edwin Chan
Chung Hang Jonathan ChoiChung Hang Jonathan Choi
Chung Hang Jonathan Choi